Role of pyridazine analogs as acetylcholinesterase inhibitor: An approach for management of alzheimer’s disease

Alzheimer s disease (AD) is a neurodegenerative disorder causing failure of cognitive aptitude and performance irregularities, resulting in degradation of cerebral and psychological activities. AD is presently a main health trouble and it is the third-major reason of casualty in the developed nations after cardiac and cancer diseases. The physiological pathway of this disorder remains almost unknown. The present curative advances to AD pursue the cholinergic theory. The acetylcholinesterase (AChE) enzyme has an essential role in the therapy of AD. The AChE-inhibitors have been developed into the leading approach for the advance of anti-ADs. Some AChE-inhibitors, like donepezil, tacrine, rivastigmine and ensaculin have shown progress in memory and cognitive actions. However, ensaculin is a coumarin analog that has prevented or lowered the progressive neurodegeneration. Several considerations support that some pyridazine analogs act as AChE and BuAChE inhibitors.